Background:At present, in clinical practice, patients with primary
hyperaldosteronism (PA) are mainly treated by surgery or medical drugs
(spironolactone/spironolactone, epridone, etc.). Some studies show that the
left ventricular hypertrophy of patients can be significantly improved after
treatment. However, at present, the relevant research is very limited, and
there is still controversy on the improvement of cardiac structure and function
between the two treatment methods. No reliable conclusions have been drawn. Objective: We conducted
this meta-analysis to compare the improvement of cardiac structure of patients
after surgical treatment and drug treatment, so as to clarify the efficacy of
surgical treatment and drug treatment for PA patients. Methods: In order
to examine the cardiac color ultrasound data of PA patients receiving surgical
treatment and drug therapy (spironolactone, antisterone), randomized or
observational studies were searched through Pubmed, Cochrane Library, and
Embase. Meta-analysis was then carried out on the comprehensive and individual
outcomes. The ROINBS-I scale is utilized to assess the offset risk of study
inclusion. Outcomes: A total of nine studies involving 799 patients with
PA into meta analysis, according to the results of the surgery in the treatment
of patients with PA, left ventricular mass index (LVMI) changes in value (drop
range) is significantly higher than drug therapy (Mean difference IV:—2.32,
P < 0.05).In 6
studies, after surgical treatment of interventricular septal thickness (IVSD), changes in value (drop
range) are also higher than drug therapy (Mean difference IV: —0.35, P < 0.05).In 2 studies, the surgical
treatment of plasma aldosterone concentration (PAC) drop degree is superior to
drug therapy (Mean difference IV:
References
[1]
Brown, J.M., Siddiqui, M., Calhoun, D.A., Carey, R.M., Hopkins, P.N., Williams, G.H., et al. (2020) The Unrecognized Prevalence of Primary Aldosteronism: A Cross-Sectional Study. Annals of Internal Medicine, 173, 10-20. https://doi.org/10.7326/M20-0065
[2]
Käyser, S.C., Dekkers, T., Groenewoud, H.J., Van der Wilt, G.J., Bakx, C.J., Van der Wel, M.C., et al. (2016) Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. The Journal of Clinical Endocrinology & Metabolism, 101, 2826-2835. https://doi.org/10.1210/jc.2016-1472
[3]
Monticone, S., D’Ascenzo, F., Moretti, C., Williams, T.A., Veglio, F., Gaita, F., et al. (2018) Cardiovascular Events and Target Organ Damage in Primary Aldosteronism Compared with Essential Hypertension: A Systematic Review and Meta-Analysis. The Lancet Diabetes Endocrinology, 6, 41-50. https://doi.org/10.1016/S2213-8587(17)30319-4
[4]
Freel, E.M., Mark, P.B., Weir, R.A., McQuarrie, E.P., Allan, K., Dargie, H.J., et al. (2012) Demonstration of Blood Pressure-Independent Noninfarct Myocardial Fibrosis in Primary Aldosteronism: A Cardiac Magnetic Resonance Imaging Study. Circulation: Cardiovascular Imaging, 5, 740-747. https://doi.org/10.1161/CIRCIMAGING.112.974576
[5]
Tsai, C.-H., Pan, C.-T., Chang, Y.-Y., Chen, Z.-W., Wu, V.-C., Hung, C.-S. and Lin, Y.-H. (2021) Left Ventricular Remodeling and Dysfunction in Primary Aldosteronism. Journal of Human Hypertension, 35, 131-147. https://doi.org/10.1038/s41371-020-00426-y
[6]
Rossi, G.P., Sacchetto, A., Visentin, P., Canali, C., Graniero, G.R., Palatini, P. and Pessina, A.C. (1996) Changes in Left Ventricular Anatomy and Function in Hypertension and Primary Aldosteronism. Hypertension, 27, 1039-1045. https://doi.org/10.1161/01.HYP.27.5.1039
[7]
Lombes, M., Alfaidy, N., Eugene, E., Lessana, A., Farman, N. and Bonvalet, J.P. (1995) Prerequisite for Cardiac Aldosterone Action. Mineralocorticoid Receptor and 11β-Hydroxysteroid Dehydrogenase in the Human Heart. Circulation, 92, 175-182. https://doi.org/10.1161/01.CIR.92.2.175
[8]
Rossi, G.P. (2006) Cardiac Consequences of Aldosterone Excess in Human Hyper Tension. American Journal of Hypertension, 19, 10-12. https://doi.org/10.1016/j.amjhyper.2005.08.011
[9]
Milliez, P., Girerd, X., Plouin, P.F., Blacher, J., Safar, M.E. and Mourad, J.J. (2005) Evidence for an Increased Rate of Cardiovascular Events in Patients with Primary Aldosteronism. Journal of the American College of Cardiology, 45, 1243-1248. https://doi.org/10.1016/j.jacc.2005.01.015
[10]
Matsumura, K., Fujii, K., Oniki, H., Oka, M. and Iida, M. (2006) Role of Aldosterone in Left Ventricular Hypertrophy in Hypertension. American Journal of Hypertension, 19, 13-18. https://doi.org/10.1016/j.amjhyper.2005.05.013
[11]
Mulatero, P., Sechi, L.A., Williams, T.A., Lenders, J.W.M., Reincke, M., Satoh, F., et al. (2020) Subtype Diagnosis, Treatment, Complications and Outcomes of primary Aldosteronism and Future Direction of Research: A Position Statement and Consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 38, 1929-1936. https://doi.org/10.1097/HJH.0000000000002520
[12]
Funder, J.W., Carey, R.M., Mantero, F., Murad, M.H., Reincke, M., Shibata, H., et al. (2016) The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 101, 1889-1916. https://doi.org/10.1210/jc.2015-4061
[13]
Sterne, J.A., Hernan, M.A., Reeves, B.C., et al. (2016) Robins-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions. BMJ, 355, i4919. https://doi.org/10.1136/bmj.i4919
[14]
Catena, C., et al. (2007) Long-Term Cardiac Effects of Adrenalectomy or Mineralocorti-Coid Antagonists in Patients with Primary Aldosteronism. Hypertension, 50, 911-918. https://doi.org/10.1161/HYPERTENSIONAHA.107.095448
[15]
Gilberta, G., et al. (2007) Aldosterone as a Key Mediator of the Cardiometabolic Syndrome in Primary Aldosteronism: An Observational Study. Journal of Hypertension, 25, 177-186. https://doi.org/10.1097/HJH.0b013e3280108e6f
[16]
Rossi, G.P., et al. (2013) Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy with Treatment of Primary Aldosteronism. Hypertension, 62, 62-69. https://doi.org/10.1161/HYPERTENSIONAHA.113.01316
[17]
Indra, T., et al. (2015) Long-Term Effects of Adrenalectomy or Spironolactone on Blood Pressure Control and Regression of Left Ventricle Hypertrophy in Patients with Primary Aldosteronism. Journal of the Renin-Angiotensin Aldosterone System, 16, 1109-1117. https://doi.org/10.1177/1470320314549220
[18]
Catena, C., et al. (2016) Dietary Salt Intake Is a Determinant of Cardiac Changes after Treatment of Primary Aldosteronism a Prospective Study. Hypertension, 68, 204-212. https://doi.org/10.1161/HYPERTENSIONAHA.116.07615
[19]
Adolf, C., et al. (2018) Cortisol Excess in Patients with Primary Aldosteronism Impacts Left Ventricular Hypertrophy. The Journal of Clinical Endocrinology & Metabolism, 103, 4543-4552. https://doi.org/10.1210/jc.2018-00617
[20]
Köhler, A. (2021) Renin a Marker for Left Ventricular Hypertrophy in Primary Aldosteronism: A Cohort Study.
[21]
Chen, Y.-L., et al. (2021) A Prospective Comparative Study on Cardiac Alterations after Surgery and Drug Treatment of Primary Aldosteronism. Frontiers in Endocrinology, 12, Article 770711.
[22]
Arleen, A., et al. (2022) Persistent Cardiac Organ Damage in Surgically and Medically Treated Primary Aldosteronism. Journal of Hypertension, 40, 1204-1211. https://doi.org/10.1097/HJH.0000000000003135
[23]
Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [Updated September 2009]. Part 3: Special Topics: 16.1.3.2. Imputing Standard Deviations for Changes from Baseline. https://handbook-5-1.cochrane.org/v5.0.2/
[24]
Catena, C., Colussi, G., Lapenna, R., et al. (2007) Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients with Primary Aldosteronism. Hypertension, 50, 911-918. https://doi.org/10.1161/HYPERTENSIONAHA.107.095448
[25]
Rossi, G.P., Cesari, M., Cuspidi, C., et al. (2013) Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy with Treatment of Primary Aldosteronism. Hypertension, 62, 62-69. https://doi.org/10.1161/HYPERTENSIONAHA.113.01316
[26]
Goldkorn, R., Yurenev, A., Blumenfeld, J., et al. (2002) Echocardiographic Comparison of Left Ventricular Structure and Function in Hypertensive Patients with Primary Aldoste-Ronism and Essential Hypertension. American Journal of Hypertension, 15, 340-345. https://doi.org/10.1016/S0895-7061(01)02331-7
[27]
Yoshihara, F., Nishikimi, T., Yoshitomi, Y., et al. (1996) Left Ventricular Structural and Func-Tional Characteristics in Patients with Renovascular Hypertension, Primary Aldoste-Ronism and Essential Hypertension. American Journal of Hypertension, 9, 523-528. https://doi.org/10.1016/0895-7061(96)00031-3
[28]
Weber, K. and Brilla, C. (1991) Pathological Hypertrophy and Cardiac Intersticium Fibrosis and Renin-Angiotensin-Aldosterone System. Circulation, 83, 1849-1865. https://doi.org/10.1161/01.CIR.83.6.1849
[29]
Makhanova, N., Hagaman, J., Kim, H.S., et al. (2008) Salt-Sensitive Blood Pressure in Mice with Increased Expression of Aldosterone Synthase. Hypertension, 51, 134-140. https://doi.org/10.1161/HYPERTENSIONAHA.107.098897
[30]
Funder, J. (2001) Mineralocorticoids and Cardiac Fibrosis: The Decade in Review. Clinical and Experimental Pharmacology and Physiology, 28, 1002-1006. https://doi.org/10.1046/j.1440-1681.2001.03586.x
[31]
Huang, W.-C., Chen, Y.-Y., Lin, Y.-H. and Chueh, J.S. (2021) Composite Cardiovascular Outcomes in Patients with Primary Aldosteronism Undergoing Medical versus Surgical Treatment: A Meta-Analysis. Frontiers in Endocrinology, 12, Article 644620. https://doi.org/10.3389/fendo.2021.644260
[32]
Walz, M.K., Gwosdz, R., Levin, S.L., et al. (2008) Retroperitoneoscopic Adrenalectomy in Conn’s Syndrome Caused by Adrenal Adenomas or Nodular Hyperplasia. World Journal of Surgery, 32, 847-853. https://doi.org/10.1007/s00268-008-9513-0
[33]
Zarnegar, R., Lee, J., Brunaud, L., et al. (2007) Good Blood Pressure Control on Antihypertensives, Not Only Response to Spironolactone, Predicts Improved Outcome after Adrenalectomy for Aldosteronoma. Surgery, 142, 921-929. https://doi.org/10.1016/j.surg.2007.09.001
[34]
Zhang, X., Zhu, Z., Xu, T. and Shen, Z. (2013) Factors Affecting Complete Hypertension Cure after Adrenalectomy for Aldosterone-Producing Adenoma: Outcomes in a Large Series. Urologia Internationalis, 90, 430-434. https://doi.org/10.1159/000347028
